



ANANDA
DEVELOPMENTS

UK Medical Cannabis Production

AQSE: ANA

Melissa Sturgess, CEO

ir@anandadevelopments.com



Disclaimer

The information contained in these slides and the accompanying verbal presentation (together the "Presentation") is being supplied to you by Ananda Developments plc on behalf of itself and its subsidiaries (together, "Ananda"). By accepting this Presentation, you agree to be bound by the following limitations. The content of this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (as amended) ("FSMA"), the Financial Conduct Authority or Acquis Exchange plc.

The merits and suitability of any investment action in relation to securities should be considered carefully and involve, among other things, an assessment of the legal, tax, accounting, regulatory, financial, credit and other related aspects of such securities. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.

This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities (including, without limitation, to any person or in any jurisdiction to whom or in which such offer or solicitation is unlawful), nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever or constitute an invitation or inducement to engage in investment activity under section 21 of FSMA, other than where a permitted exemption is available to them.

Notwithstanding the above, this Presentation is only being given to persons reasonably believed by Ananda to be in the United Kingdom who are: (1) investment professionals within the meaning of article 19, certified high net worth individuals within the meaning of article 48, high net worth companies within the meaning of article 49, sophisticated investors within the meaning of article 50 and self-certified sophisticated investors within the meaning of article 50A of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended; or (2) "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) as amended, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018; and (iii) persons who are otherwise permitted by law to receive it (all such persons together being referred to as "relevant persons"). This Presentation is only being sent to persons reasonably believed by Ananda to be relevant persons. If you are not such a relevant person (i) you should not have received this Presentation and (ii) please return this Presentation to Ananda as soon as possible and take no other action.

The information in this Presentation or on which this Presentation is based has been obtained from sources that Ananda believes to be reliable and accurate. However, none of Ananda, Ananda's directors, officers, employees, its shareholders or any of their respective advisors, or any other person has independently verified the information in this presentation and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation and no reliance should be placed on such information or opinions.

Neither Ananda, nor its related bodies corporate, directors, officers, partners, advisers, agents and/or employees accept any responsibility or liability to you or any other person or entity arising out of this Presentation, including pursuant to the general law (whether for negligence, under statute or otherwise) any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

The information in this Presentation is for general information only. To the extent that certain statements contained in this presentation may constitute "forward-looking statements" or statements about "future matters", the information reflects Ananda's intent, belief or expectations at the date of this presentation. In some cases forward looking statements can be identified by the use of terms such as "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or variations thereof, or by discussions of strategy, plans, objectives, goals, future events or intentions. Subject to any continuing obligations under applicable law, Ananda disclaims any obligation or undertaking to provide you with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from this presentation which may become apparent.

Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ananda's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any opinions, projections, estimates or forecasts contained in this Presentation constitute a judgment of Ananda only and should not be relied upon, and are provided as at the date of this Presentation and are subject to change without notice. This information is subject to change without notice. The accuracy of such information is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning Ananda and its subsidiaries. The forward-looking information contained in this Presentation is expressly qualified by this cautionary statement.

Neither this Presentation nor any copy of it may be taken, distributed, published, transmitted or otherwise made available in whole or in part, directly or indirectly, into or within the United States, Australia, Canada, the Republic of South Africa, the Republic of Ireland or Japan (each a "Restricted Territory"), their territories or possessions, or distributed to any individual outside a Restricted Territory who is a resident thereof, in any such case for the purpose of an offer for sale or solicitation or invitation to buy or subscribe for securities in Ananda, or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case, except in compliance with any applicable exemption from requirements surrounding the circulation of such materials and the solicitation of investors. The securities of Ananda have not been, and will not be, registered under the United States Securities Act of 1933 ("Securities Act") or with any securities regulatory authority of any state or jurisdiction of the United States and may not be offered, sold, resold, or transferred, directly or indirectly, into or within the United States unless registered under the Securities Act, or pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act or in compliance with any applicable securities laws of any state or jurisdiction of the United States.

By accepting this Presentation, you agree to be bound by the provisions, the limitations and conditions set out in this disclaimer and, in particular, you have represented, warranted and undertaken that: (1) you are a relevant person and you will observe the foregoing provisions, limitations and conditions, (2) you have read and agree to comply with the contents of this disclaimer; and (3) you agree to keep permanently confidential the information contained in this Presentation or made available in connection with further enquiries to the extent such information is not made publicly available (otherwise through a breach by you of this provision).


UK and European Medical Cannabis Market

- ◆ UK Market expected to be worth £450 million in 2025*
- ◆ EU Market expected to be worth €3.2 billion (£2.7 billion) in 2025**

*Arcview The State of the Legal Cannabis Markets 8th Edition 2021

**Prohibition Partners European Cannabis Report 6th Edition, 2021

Projected growth of European cannabis market



Source: Prohibition Partners/Atalis

Regulation and Industry Growth

The UK is starting to get to grips with medical cannabis



Legalisation of medical cannabis in Nov 2018

Industry is growing in the same way it did in other countries

In the UK the private sector is leading the way:

- ◆ 3,000 patients in Jan 2021
- ◆ 6,000 patients in April 2021
- ◆ 9,500 patients in Sept 2021

Usual growth profile: minimal growth for 2 years after legalisation, slow growth in years 3 and 4 and then exponential growth:


- ◆ Germany legalised medical cannabis in 2017. Patient numbers have increased tenfold since the first year to 120,000 in 2020** from a population of 83 million
- ◆ Israel had 10,000 medical cannabis patients in 2012 and now has more than 80,000 from a population of 9 million

MHRA (Medicines and Healthcare Products Regulatory Agency) and NICE (National Institute for Health and Care Excellence) wanting to see Random Controlled Trials and will consider real world evidence(which is different from anecdotal evidence)

There is a high probability that the public sector will follow the private sector



Progress to Date



Investment Summary

Ananda's objective is to grow and provide carbon neutral, consistent, high quality medical cannabis for the UK and international markets.

Ananda's strategy is in two Phases:

Phase One

- ◆ UK Home Office Licence to grow >0.2% THC cannabis for research – Granted
- ◆ Research phase: genetic stabilisation of 65 strains and choice of strains for identified agronomical traits and medical efficacy

Phase Two

- ◆ Apply to UK Home Office Licence to grow >0.2% THC cannabis for commercial purposes

Only imported medical cannabis currently available in the UK – demand for domestic supply of premium medical cannabis – quality, science, transparency, availability

The UK is a global gold standard jurisdiction in medical and pharmaceutical regulation

Ananda's team has the benefit of 3 years experience and R&D expenditure growing 5 hectares of medical cannabis

Co-operative research agreement with Prof Dedi Meiri who runs world leading cannabinoid research laboratory at the Technion in Israel

Ananda's Head Grower previously Head Grower for BOL Pharma in Israel





Phase One
has commenced

- ◆ Produce 65 genetically stable strains of cannabis developed from a breeding programme of 13 strains of cannabis exhibiting varying metabolic profiles (THC/CBD, minor cannabinoids, terpenes and flavonoids)
- ◆ In collaboration with Dr Dedi Meiri of the Technion Institute in Israel, analyse and assess for hundreds of cannabinoids, flavonoids and terpenes
- ◆ Grow strains to identify agronomical traits – to ensure best production for local conditions
- ◆ Finalise and choose strains for indications with focus on pain, systemic sclerosis (skin inflammation), epilepsy and Parkinson's Disease
- ◆ Chose several of the stable strains to be suitable for Phase 2 commercial growing
- ◆ Extraction trials
- ◆ Negotiate offtake agreements for commercial growing, subject to Home Office licensing



02

Phase Two

subject to further Home
Office licensing

- ◆ Expand research location to convert to commercial growing up to 30 hectares in multi-chapelle structures
- ◆ Focus on agronomic excellence – GACP (Good Agricultural and Collection Practice)
- ◆ Complete GMP certification
- ◆ Install extraction capacity
- ◆ Utilise our partner JEPCO's QMS (quality management system) systems, people, procedures, processes
- ◆ Ananda will sell premium CBPMs (cannabis based products for medical use in humans) and later APIs (active pharmaceutical ingredients)

Ananda's Approach

Ananda will use its proven low capex, low opex, natural season approach

Near zero greenhouse gas emission - No artificial light or heat

Location is ideal for growing cannabis in multi-chapelle structures and provides a low diurnal variation in temperature (warmer nights/cooler days)

Multi-chapelle structures are very flexible, allowing precise airflow management to create stable temperature and humidity

Low cost and clean and green in an industry that isn't!

Non-dilutive funding opportunities (Grant funding)

DLI mol d⁻¹m⁻² by period



The Board

Charles Morgan

Chairman

Successful oil entrepreneur with major monetisation track record. Investor in tech and biotech. Honorary PhD for services to commercialisation of science. Co-founder of Ananda.

Stuart Piccaver

Executive Director (joining)

Stuart Piccaver is a third generation farmer and CEO of JEPCO Farming. With a background and interest in marketing and innovation he has been the driving force for many of the leading agricultural initiatives of the JEPCO Group.

Simon Goddard

Executive Director (joining)

Simon Goddard is a qualified accountant and has been CFO of the JEPCO and Anglia Groups for 19 years. He is also responsible for the Group's CSR and technical quality standards.

Melissa Sturgess

CEO

Co-founder of Ananda and experienced listed company director. Strong and successful team builder in complex situations and jurisdictions.

John Treacy

Independent Non-Executive Director

Corporate Lawyer, experienced listed company corporate financier. John Treacy has vast experience guiding quoted companies effectively through their early growth years.

Dr Inbar Maymon Pomeranchik, PhD

Executive Director

Dr. Inbar Maymon-Pomeranchik is a Scientist and Biotech investment consultant expert, specializing in Life Science, Biotech, Ag-Tech and is a leading scientific expert in the global medical cannabis industry.

Advisors and Partners

Dr Hadar Less

Cannabis Geneticist
Ex Head Grower for BOL Pharma

Dr Eli Schmell

Scientific Protocol Advisor
Expert in FDA approval processes and working to
common technical standards

Dr Dedi Meiri

Technion Israel
Global leading medical cannabis researcher

Prof Marie Fallon

Palliative Care Specialist
Edinburgh

Peterhouse Capital Limited

Corporate Broker and Corporate Finance Advisor

PKF Littlejohn

Auditors

Memery Crystal

Corporate and Publicly Listed Company Law

BCL

Lawyers

Maple Tree Consultants

Medical Cannabis Industry Consultants

Mitkmark

Security Advisors

Peter French

Security Advisor

LISTING DETAILS

MARKET

Aquis Growth Market

TICKER

AQSE: ANA

SHARE PRICE

*.9p

MARKET CAP

*£7M

SHARES IN ISSUE

*790,538,886

Corporate Details

Holder	No. of Shares	%
Melissa Sturgess	176,500,837	22.33%
Charles Morgan	145,541,666	18.41%
Barnard Nominees Limited	83,810,000	10.60%
Lynchwood Nominees Limited	43,500,000	5.50%
Jim Nominees Limited	43,399,880	5.49%
Hargreaves Lansdown /Nominees/ Limited	43,362,351	5.49%
Pershing Nominees Limited	30,335,000	3.84%
Hargreaves Lansdown /Nominees/ Limited	29,322,227	3.71%
Redmayne /Nominees/ Limited	23,888,889	3.02%
The Bank Of New York /Nominees/ Limited	14,547,891	1.84%
Total	634,208,741	80.22%

Summary



- ◆ Licence application submitted October 2019 with research plan to grow and genetically stabilise 65 strains of cannabis. Licence granted May 2021
- ◆ Early mover in UK medical cannabis cultivation – experienced team, right climate and strong regulatory jurisdiction
- ◆ UK is a pre-eminent medical and pharmaceutical jurisdiction
- ◆ The medical cannabis industry is growing rapidly and is not a cyclical sector
- ◆ Best in class multidisciplinary team: strong combination of corporate, scientific, agronomic and horticultural skills
- ◆ Defensive barriers to entry
- ◆ 2 Phase plan to grow for commercial purposes : focus on research and growing excellence and low cost of production
 - DJT Plants Ltd spent 3 years growing for GW Pharmaceuticals
 - Ananda's head grower previous head grower for BOL Pharma of Israel
 - Co-operative agreement with prof Dedi Meiri of Technion Institute of Technology, Haifa, Israel – pre eminent cannabis scientist



ANANDA
DEVELOPMENTS